Kezar Life Sciences Inc. Stock Analysis KZR

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. The company is headquartered in South San Francisco, California and currently employs 9 full-time employees. The company went IPO on 2018-06-21. The firm's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The firm is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.